JP2009507052A - ピリミジン誘導体およびそのｋｃｎｑカリウムチャネル開口薬としての使用 - Google Patents

ピリミジン誘導体およびそのｋｃｎｑカリウムチャネル開口薬としての使用 Download PDF

Info

Publication number
JP2009507052A
JP2009507052A JP2008529473A JP2008529473A JP2009507052A JP 2009507052 A JP2009507052 A JP 2009507052A JP 2008529473 A JP2008529473 A JP 2008529473A JP 2008529473 A JP2008529473 A JP 2008529473A JP 2009507052 A JP2009507052 A JP 2009507052A
Authority
JP
Japan
Prior art keywords
disorder
alkenyl
alkyl
alkynyl
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008529473A
Other languages
English (en)
Japanese (ja)
Inventor
カーンジン・ニコライ
グレーヴェ・ダニエル・ロドリグェス
ロットレンダー・マーリオ
Original Assignee
ハー・ルンドベック・アクチエゼルスカベット
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハー・ルンドベック・アクチエゼルスカベット filed Critical ハー・ルンドベック・アクチエゼルスカベット
Publication of JP2009507052A publication Critical patent/JP2009507052A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2008529473A 2005-09-09 2006-09-07 ピリミジン誘導体およびそのｋｃｎｑカリウムチャネル開口薬としての使用 Withdrawn JP2009507052A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200501262 2005-09-09
PCT/DK2006/050039 WO2007065449A1 (fr) 2005-09-09 2006-09-07 Derives de pyrimidine et leur emploi en tant qu'agents ouvrant les canaux potassiques kcnq

Publications (1)

Publication Number Publication Date
JP2009507052A true JP2009507052A (ja) 2009-02-19

Family

ID=37199174

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008529473A Withdrawn JP2009507052A (ja) 2005-09-09 2006-09-07 ピリミジン誘導体およびそのｋｃｎｑカリウムチャネル開口薬としての使用

Country Status (15)

Country Link
EP (1) EP1937653A1 (fr)
JP (1) JP2009507052A (fr)
KR (1) KR20080043314A (fr)
CN (1) CN101258133A (fr)
AR (1) AR055420A1 (fr)
AU (1) AU2006322461A1 (fr)
BR (1) BRPI0615631A2 (fr)
CA (1) CA2621854A1 (fr)
EA (1) EA200800780A1 (fr)
IL (1) IL189545A0 (fr)
MX (1) MX2008002294A (fr)
NO (1) NO20081713L (fr)
UA (1) UA93387C2 (fr)
WO (1) WO2007065449A1 (fr)
ZA (1) ZA200802174B (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013531006A (ja) * 2010-07-08 2013-08-01 ファイザー・インク Ｋｖ７カリウムチャネル開口薬としてのピペリジニルピリミジンアミド
JP2018048143A (ja) * 2014-10-24 2018-03-29 小野薬品工業株式会社 Ｋｃｎｑ２〜５チャネル活性化剤

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100256145A1 (en) * 2007-08-01 2010-10-07 H. Lundbeck A/S Use of kcnq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
WO2010097379A1 (fr) * 2009-02-24 2010-09-02 Neurosearch A/S Dérivés pyrimidine substitués et leur utilisation médicale
CA2815131C (fr) * 2010-10-20 2020-06-09 Gruenenthal Gmbh 6-amino-nicotinamides substitues en tant que modulateurs des kcnq2/3
CN103508960B (zh) * 2012-06-29 2017-12-12 江苏先声药业有限公司 苯并杂环衍生物
CN103508943B (zh) * 2012-06-29 2017-06-09 江苏先声药业有限公司 作为钾通道调节剂的化合物
JP2022543230A (ja) * 2019-08-02 2022-10-11 ハー・ルンドベック・アクチエゼルスカベット てんかん又はてんかん発作において使用するためのＫｖ７カリウムチャネル開口薬としてのアルコール誘導体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508833A (ja) * 2001-02-20 2005-04-07 ブリストル−マイヤーズ　スクイブ　カンパニー Ｋｃｎｑカリウムチャネル・モジュレーターとしての２，４−ジ置換ピリミジン−５−カルボキサミド誘導体
AU2003202115A1 (en) * 2002-02-12 2003-09-04 Pfizer Inc. Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh)
US20080261918A1 (en) * 2004-12-17 2008-10-23 Graham Andrew Showell Silicon Compounds and Their Use

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013531006A (ja) * 2010-07-08 2013-08-01 ファイザー・インク Ｋｖ７カリウムチャネル開口薬としてのピペリジニルピリミジンアミド
JP2018048143A (ja) * 2014-10-24 2018-03-29 小野薬品工業株式会社 Ｋｃｎｑ２〜５チャネル活性化剤
US10676438B2 (en) 2014-10-24 2020-06-09 Ono Pharmaceutical Co., Ltd. KCNQ2-5 channel activator

Also Published As

Publication number Publication date
WO2007065449A1 (fr) 2007-06-14
KR20080043314A (ko) 2008-05-16
AU2006322461A1 (en) 2007-06-14
NO20081713L (no) 2008-06-04
CN101258133A (zh) 2008-09-03
UA93387C2 (ru) 2011-02-10
ZA200802174B (en) 2009-10-28
IL189545A0 (en) 2008-06-05
EP1937653A1 (fr) 2008-07-02
AR055420A1 (es) 2007-08-22
MX2008002294A (es) 2008-03-14
EA200800780A1 (ru) 2008-06-30
BRPI0615631A2 (pt) 2011-05-24
CA2621854A1 (fr) 2007-06-14

Similar Documents

Publication Publication Date Title
JP5237643B2 (ja) 置換されたピリジン誘導体
JP5006184B2 (ja) 置換されたモルホリンおよびチオモルホリン誘導体
US7683058B2 (en) Substituted pyrimidine derivatives
JP2009507052A (ja) ピリミジン誘導体およびそのｋｃｎｑカリウムチャネル開口薬としての使用
JP2008512402A (ja) 置換されたアニリン誘導体
US20060264496A1 (en) Substituted indoline and indole derivatives
US7906537B2 (en) Substituted p-diaminobenzene derivatives
JP2006515300A (ja) 中枢神経系の疾患の治療に有用な１，２，４−トリアミノベンゼン誘導体
JP2006520333A (ja) 置換されたアニリン誘導体
KR20050117563A (ko) 치환 아닐린 유도체
NZ541999A (en) Substituted indoline and indole derivatives
KR20070108884A (ko) 치환된 피리딘 유도체
HRP20080507A2 (hr) Supstituirani derivati morfolina i tiomorfolina
KR20050089862A (ko) 중추신경계 장애의 치료에 유용한 1,2,4-트리아미노벤젠유도체
MXPA06010329A (en) Substituted morpholine and thiomorpholine derivatives

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090817

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20100519

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20110329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110330